The astrocyte-produced growth factor HB-EGF limits autoimmune CNS pathology
Mathias Linnerbauer1, Lena Lößlein1, Oliver Vandrey1
1Department of Neurology, University Hospital Erlangen, Friedrich-Alexander University Erlangen Nuremberg, Erlangen, Germany.
Nature Immunology
|February 26, 2024
Summary
Heparin-binding EGF-like growth factor (HB-EGF) promotes tissue protection and resolves inflammation in the central nervous system (CNS). This discovery offers a potential therapeutic target for multiple sclerosis (MS) and related autoimmune neuroinflammatory diseases.
Area of Science:
- Neuroimmunology
- Cellular Biology
- Molecular Medicine
Background:
- Central nervous system (CNS)-resident glial cells, including microglia and astrocytes, play complex roles in neuroinflammatory diseases like multiple sclerosis (MS).
- While pro-inflammatory glial responses are well-documented in MS pathogenesis, their potential for resolving inflammation and protecting tissue is increasingly recognized.
- Dysregulation of these protective mechanisms can exacerbate disease progression and conversion to chronic forms of MS, highlighting a critical unmet therapeutic need.
Purpose of the Study:
- To identify key mediators of tissue protection and anti-inflammatory effects in CNS autoimmunity.
- To investigate the role of Heparin-binding EGF-like growth factor (HB-EGF) in the recovery from inflammatory lesions in the CNS.
- To explore the regulation and therapeutic potential of HB-EGF in preclinical models of MS.
Main Methods:
- Proteomic analysis of cerebrospinal fluid from MS patients.
- In vitro studies on various cell types to assess HB-EGF effects.
- Experimental studies in a preclinical mouse model of MS, including intranasal HB-EGF administration.
Main Results:
- Heparin-binding EGF-like growth factor (HB-EGF) was identified as a central mediator of tissue-protective and anti-inflammatory effects.
- Hypoxia upregulates astrocyte HB-EGF during early CNS inflammation; pro-inflammatory conditions suppress HB-EGF signaling via epigenetic modifications.
- Intranasal HB-EGF administration attenuated disease in a preclinical mouse model of MS, demonstrating anti-inflammatory and tissue-protective effects.
Conclusions:
- Astrocyte-derived HB-EGF is a crucial modulator of autoimmune CNS inflammation and recovery.
- Epigenetic regulation of HB-EGF influences its trophic and anti-inflammatory signaling.
- HB-EGF represents a promising therapeutic target for multiple sclerosis and other autoimmune neuroinflammatory conditions.
